Health Canada Approves Venetoclax for CLL Patients With 17P deletion or if No Other Treatment Options are Available

Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for VENCLEXTA™ (venetoclax), a promising oral therapy for the treatment of patients with chronic lymphocytic leukemia (CLL).

The therapy has been approved for previously treated chronic lymphocytic leukemia (CLL) patients, who have either a genetic mutation, known as 17p deletion, or no other available treatment options. Under NOC/c policy, AbbVie will provide Health Canada with data from additional studies to confirm the clinical benefit of VENCLEXTA..

You can read more at: http://www.newswire.ca/news-releases/abbvies-new-oral-therapy-venclexta-now-available-for-canadians-with-a-difficult-to-treat-blood-cancer-595962181.html

Like with Social Media